Lucius Revumenib online kaufen

Price range: MYR 242.67 through MYR 1,282.67

1,500+ terjual
Harga Promosi

Farmasi fizikal Hong Kong dengan jaminan produk tulen 100%

Sorotan Produk

FDA Revuforj / REVUMENIB Syndax Pharmaceuticals, Inc. ORAL 1 INDICATIONS AND USAGE REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. ( 1 ) the t

Jaminan Perkhidmatan

Penghantaran Rentas SempadanFarmasi BerlesenDisemak Ahli FarmasiJaminan Ketulenan

Spesifikasi

Spesifikasi
25mg*30 110mg*30 160mg*30
Pengilang
Lucius Pharmaceuticals
Penghantaran
Hong Kong
SKU: N/A Category: Tag: Brand:

Maklumat Produk

Nama Jepun
Revumenib
Nama Inggeris
Revumenib
Nama Cina
Revumenib
Nama Generik
Revumenib

Spesifikasi

Spesifikasi
25mg*30 110mg*30 160mg*30
Pengilang
Lucius Pharmaceuticals
Penghantaran
Hong Kong

Butiran Penuh

Indikasi

Revumenib ,

Mekanisme Tindakan

Revumenib Mekanisme Tindakan Mekanisme Tindakan ,

Dos dan Cara Penggunaan

2 KMT2A NPM1 REVUFORJ (2.1) REVUFORJ , , (2.2) REVUFORJ , (2.2, 2.3) 2.1 KMT2A KMT2A REVUFORJ [ (14.1)] FDA KMT2A , [ ] NPM1 NPM1 REVUFORJ

Langkah Berjaga-jaga

5 Langkah Berjaga-jaga - , , (5.3, 8.1, 8.3) 5.1 REVUFORJ (DS) , REVUFORJ , / ,241 REVUFORJ , 60 (25%) DS [ (6.1)] KMT2A ,DS 33% AML ,33% MPAL 9% ALL

Package Insert

Ingredients

11 REVUFORJ revumenib , menin , ,N- -2-[[4-[7-[[ -4-[( ) ] ] ]-2,7- [3.5] -2- ]-5- ] ]-5- -N-[1- ]-,2- -1,2,3- (1:1:1) C32H47FN6O4S●C6H8O7●H2O, 840.96 g/mol pH 1.2 6.8 , pH 4.5

Indications

Revumenib ,

Dos dan Cara Penggunaan

2 KMT2A NPM1 REVUFORJ (2.1) REVUFORJ , , (2.2) REVUFORJ , (2.2, 2.3) 2.1 KMT2A KMT2A REVUFORJ [ (14.1)] FDA KMT2A , [ ] NPM1 NPM1 REVUFORJ

Precautions

5 Langkah Berjaga-jaga - , , (5.3, 8.1, 8.3) 5.1 REVUFORJ (DS) , REVUFORJ , / ,241 REVUFORJ , 60 (25%) DS [ (6.1)] KMT2A ,DS 33% AML ,33% MPAL 9% ALL

Use in Pregnancy and Lactation

8.1 Mekanisme Tindakan[ (12.1)],REVUFORJ REVUFORJ , , revumenib, , - , AUC 0.5 ,

Clinical Pharmacology

12 12.1 Mekanisme Tindakan menin , 2A (KMT2A) KMT2A menin KMT2A KMT2A menin , NPM1 KMT2A NPM1 , NPM1 (AML) , NPM1 A B D KMT2A , revumenib menin-KMT2A t

Clinical Studies

14 14.1 KMT2A SNDX-5613-0700 REVUFORJ SNDX-5613-0700,NCT04065399 AUGMENT-101 30 , KMT2A (R/R) 11q23 QTcF < 450 , ≥ 60 mL/min/1.73 m², < (ULN) 1.5 , < ULN 3 , > 50% ≥ 18 , (ECOG) 0-2 16 < 18 , (Karnofsky Performance Scale) ≥ 50 (Lansk )

Ulasan Produk (16)

Filter: All Reviews
4.8★★★★★
+o***e· 3 weeks ago
★★★★
+t***3· 1 months ago
Pembelian Disahkan
★★★★★

Penerangan produk

Indikasi

Revumenib ,

Mekanisme Tindakan

Revumenib Mekanisme Tindakan Mekanisme Tindakan ,

Dos dan Cara Penggunaan

2 KMT2A NPM1 REVUFORJ (2.1) REVUFORJ , , (2.2) REVUFORJ , (2.2, 2.3) 2.1 KMT2A KMT2A REVUFORJ [ (14.1)] FDA KMT2A , [ ] NPM1 NPM1 REVUFORJ

Langkah Berjaga-jaga

5 Langkah Berjaga-jaga - , , (5.3, 8.1, 8.3) 5.1 REVUFORJ (DS) , REVUFORJ , / ,241 REVUFORJ , 60 (25%) DS [ (6.1)] KMT2A ,DS 33% AML ,33% MPAL 9% ALL

Maklumat tambahan

Specification

25mg*30片, 110mg*30片, 160mg*30片